Anebulo Pharmaceuticals (ANEB) announced the first subjects dosed in its Phase 1 single ascending dose study of intravenous selonabant in healthy young adults. The study is supported by a collaborative grant from the National Institute on Drug Abuse.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANEB: